Intra-cellular Therapies, Inc. logo

Intra-cellular Therapies, Inc. Share Price Today (NASDAQ: ITCI)

Intra-cellular Therapies, Inc. share price is $0 & ₹0.00 as on 31 Mar 2025 IST

▲

-131.87

(-100%)

Market is closed - opens 7 PM, 09 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 1 Apr 2025

View live Intra-cellular Therapies, Inc. share price in Dollar and Rupees. Guide to invest in Intra-cellular Therapies, Inc. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Intra-cellular Therapies, Inc., along with analyst recommendations, forecasts, and comprehensive financials.

Intra-cellular Therapies, Inc. (ITCI) Key Statistics

in dollars & INR

Previous Close
$131.87
Open
$131.9
Market Capitalization
$14.1B
Today's Volume
$3.0M
Revenue TTM
$680.9M
EBITDA
$-116.2M
Earnings Per Share (EPS)
$-0.73
Profit Margin
-10.97%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-8.58%

How to invest in Intra-cellular Therapies, Inc. Stock (ITCI) from India?

It is very easy for Indian residents to invest directly in Intra-cellular Therapies, Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Intra-cellular Therapies, Inc. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Intra-cellular Therapies, Inc. or ITCI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Intra-cellular Therapies, Inc. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Intra-cellular Therapies, Inc. shares which would translate to null fractional shares of Intra-cellular Therapies, Inc. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Intra-cellular Therapies, Inc., in just a few clicks!

Global Institutional Holdings in Intra-cellular Therapies, Inc.

  • FMR Inc

    10.42%

  • Vanguard Group Inc

    9.14%

  • BlackRock Inc

    5.75%

  • JPMorgan Chase & Co

    4.82%

  • Wasatch Advisors LP

    3.06%

  • NORGES BANK

    3.02%

Analyst Recommendation on Intra-cellular Therapies, Inc.

Rating
Trend

Buy

    86%Buy

    13%Hold

    0%Sell

Based on 23 Wall street analysts offering stock ratings for Intra-cellular Therapies, Inc.(by analysts ranked 0 to 5 stars)

About Intra-cellular Therapies, Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder. In addition, the company develops lenrispodun (ITI-214) in Phase 2 clinical trial for the treatment of Parkinson's disease; ITI-1284-ODT-SL in Phase 2 trial for the treatment of generalized anxiety disorder, and psychosis and agitation in patients with Alzheimer's disease; ITI-1020 in Phase 1 trial for cancer immunotherapy; and ITI-1549 in preclinical studies for mood and anxiety disorders. It distributes its products through third-party wholesale drug distributors. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in Bedminster, New Jersey.
Organization
Intra-cellular Therapies, Inc.
Employees
860
CEO
Dr. Sharon Mates Ph.D.
Industry
Health Technology

Management People of Intra-cellular Therapies, Inc.

NameTitle
Dr. Sharon Mates Ph.D.
Co-Founder, Chairman & CEO
Mr. Michael I. Halstead J.D.
President
Mr. Sanjeev Narula
Executive VP, CFO & Treasurer
Dr. Suresh K. Durgam M.D.
Executive VP & Chief Medical Officer
Mr. Mark Neumann
EVP & Chief Commercial Officer
Dr. Robert E. Davis Ph.D.
Senior VP & Chief Scientific Officer
Mr. Juan Fernando Sanchez M.D.
Vice President of Corporate Communications & Investor Relations
Ms. Karen Patruno Sheehy Esq.
Senior VP & Chief Compliance Officer
John P. Condon
Senior VP, General Counsel & Secretary
Dr. Michael Olchaskey Pharm.D.
Senior VP & Head of Regulatory Affairs

Important FAQs about investing in ITCI Stock from India :

Can Indians buy Intra-cellular Therapies, Inc. shares?

Yes, Indians can invest in the Intra-cellular Therapies, Inc. (ITCI) from India.

With INDmoney, you can buy Intra-cellular Therapies, Inc. at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Intra-cellular Therapies, Inc. at zero transaction cost.

How can I buy Intra-cellular Therapies, Inc. shares from India?

It is very easy to buy Intra-cellular Therapies, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Intra-cellular Therapies, Inc. (ITCI) be purchased?

Yes, you can buy fractional shares of Intra-cellular Therapies, Inc. with INDmoney app.

What are the documents required to start investing in Intra-cellular Therapies, Inc. stocks?

To start investing in Intra-cellular Therapies, Inc., You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Intra-cellular Therapies, Inc.?

Today's market capitalisation of Intra-cellular Therapies, Inc. ITCI is 14.1B

Who is the Chief Executive Officer (CEO) of Intra-cellular Therapies, Inc. ?

Dr. Sharon Mates Ph.D. is the current Chief Executive Officer (CEO) of Intra-cellular Therapies, Inc..